Compounds > 1-(5-isoquinolinesulfonyl)-2-methylpiperazine
Page last updated: 2024-10-28

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Compensatory Hyperinsulinemia

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Compensatory Hyperinsulinemia in 1 studies

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.

Compensatory Hyperinsulinemia: A GLUCOSE-induced HYPERINSULINEMIA, a marker of insulin-resistant state. It is a mechanism to compensate for reduced sensitivity to insulin.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schinzari, F1
Tesauro, M1
Rovella, V1
Di Daniele, N1
Gentileschi, P1
Mores, N1
Campia, U1
Cardillo, C1

Other Studies

1 other study available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Compensatory Hyperinsulinemia

ArticleYear
Rho-kinase inhibition improves vasodilator responsiveness during hyperinsulinemia in the metabolic syndrome.
    American journal of physiology. Endocrinology and metabolism, 2012, Sep-15, Volume: 303, Issue:6

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Antioxidants; Drug Resistance; Endothelium, Va

2012